Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deepa Mocherla

Medical Oncology Las Vegas, NV Medical Doctor

NPI 1649394909 CMS profile 29148

8285 W Arby Ave Ste 100, Las Vegas, NV 89113

Open in the dashboard

General payments

$2,745

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,333 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Deepa Mocherla of Las Vegas, NV is reported in the CMS Open Payments database as having received $2,745 across 150 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,333 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 44th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78 1
2023 General $121 5
2022 General $48 2
2021 General $58 3
2020 General $327 21
2019 General $2,113 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deepa Mocherla
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Deepa Mocherla were reported at $78. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Deepa Mocherla Medical Oncology median Middle half National median
2019 $2,113 $968 $140–$6,658 $163
2020 $327 $747 $102–$5,891 $114
2021 $58 $430 $50–$4,098 $132
2022 $48 $812 $127–$4,907 $149
2023 $121 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $78 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $317 18 payments
  2. Astellas Pharma US Inc $187 8 payments
  3. AstraZeneca Pharmaceuticals LP $161 12 payments
  4. Seattle Genetics, Inc. $154 4 payments
  5. Pfizer Inc. $146 11 payments
  6. Incyte Corporation $144 5 payments
  7. Janssen Biotech, Inc. $129 8 payments
  8. Merck Sharp & Dohme Corporation $124 9 payments
  9. Novartis Pharmaceuticals Corporation $121 7 payments
  10. AbbVie, Inc. $120 6 payments
  11. Other $1,142 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,533 145 payments
  2. Education $211 5 payments
Products named General payments · program years 2019–2025
  1. Neulasta $155 9 payments
  2. XGEVA $140 8 payments
  3. Vectibix $133 7 payments
  4. KEYTRUDA $124 9 payments
  5. LIBTAYO $104 1 payment
  6. DARZALEX $99 7 payments
  7. IMBRUVICA $97 6 payments
  8. ADCETRIS $96 1 payment
  9. ZEJULA $88 4 payments
  10. TAGRISSO $80 6 payments
  11. Other $2,476 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,669

Median for Medical Oncology: 414

Drug cost

$3,535,639

Median for Medical Oncology: $849,427

Branded share of claims

31.8%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 53 $943,090
Verzenio Abemaciclib Brand 44 $654,217
Ibrance Palbociclib Brand 40 $638,991
Kisqali Ribociclib Succinate Brand 31 $514,016
Xtandi Enzalutamide Brand 27 $372,723
Imbruvica Ibrutinib Brand 17 $251,792
Thalomid Thalidomide Brand 12 $91,345
Eliquis Apixaban Brand 39 $30,558
Xarelto Rivaroxaban Brand 11 $17,938
Anastrozole Generic 363 $3,410

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$133,668

Medicare's payments for the services billed

Medicare patients

27

Average age 76

Services billed

13,141

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 52%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record